Your browser doesn't support javascript.
loading
Advancing assessment of asthma control with a composite tool: The Asthma Impairment and Risk Questionnaire.
Chipps, Bradley E; Zeiger, Robert S; Beuther, David A; Wise, Robert A; McCann, William; Reibman, Joan; George, Maureen; Gilbert, Ileen; Eudicone, James M; Coyne, Karin S; Harding, Gale; Murphy, Kevin R.
Afiliação
  • Chipps BE; Capital Allergy & Respiratory Disease Center, Sacramento, California. Electronic address: bchipps@capitalallergy.com.
  • Zeiger RS; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
  • Beuther DA; National Jewish Health, Denver, Colorado.
  • Wise RA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • McCann W; Allergy Partners, Asheville, North Carolina.
  • Reibman J; New York University School of Medicine, New York, New York.
  • George M; Columbia University School of Nursing, New York, New York.
  • Gilbert I; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Eudicone JM; BioPharmaceuticals Medical, AstraZeneca, Wilmington, Delaware.
  • Coyne KS; Evidera, Bethesda, Maryland.
  • Harding G; Evidera, Bethesda, Maryland.
  • Murphy KR; Boys Town National Research Hospital, Boys Town, Nebraska.
Ann Allergy Asthma Immunol ; 133(1): 49-56, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38494113
ABSTRACT

BACKGROUND:

National and international asthma guidelines and reports do not include control tools that combine impairment assessment with exacerbation history in one instrument.

OBJECTIVE:

To analyze the performance of the composite Asthma Impairment and Risk Questionnaire (AIRQ) in assessing both domains of control and predicting exacerbation risk compared with the Global Initiative for Asthma (GINA) 4-question symptom control tool (GINA SCT), Asthma Control Test (ACT), and physician expert opinion (EO) informed by GINA SCT responses and appraisal of GINA-identified risk factors for poor asthma outcomes.

METHODS:

Multivariable logistic regressions evaluated AIRQ and GINA SCT as predictors of ACT. McNemar's test compared the proportion of patients categorized at baseline as completely or well-controlled by each assessment but with current impairment or previous-year and subsequent-year exacerbations.

RESULTS:

The analysis included 1064 patients aged 12 years or older; mean (SD) age 43.8 years (19.3); 70% female; 79% White; and 6% Hispanic or Latino. AIRQ and GINA SCT were highly predictive of ACT well-controlled vs not well-controlled and very poorly controlled (receiver operator characteristic area under curve AIRQ = 0.90, GINA SCT = 0.86, P = .03 AIRQ vs GINA SCT) and ACT very poorly controlled vs well-controlled and not well-controlled asthma (receiver operator characteristic area under curve AIRQ = 0.91, GINA SCT = 0.87, P = .01 AIRQ vs GINA SCT). AIRQ rated fewer patients as having completely or well-controlled asthma who had current impairment (P < .01) or with previous-year and subsequent-year exacerbations (P < .001) than did GINA SCT, ACT, and EO.

CONCLUSION:

AIRQ performs better in assessing both domains of current control and predicting exacerbation risk than do control tools and EO informed by GINA SCT and risk factors for poor asthma outcomes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma Idioma: En Ano de publicação: 2024 Tipo de documento: Article